A novel approach to improve the pharmacokinetic properties of 8-chloro-adenosine by the dual combination of lipophilic derivatisation and liposome formulation.

doi:10.1016/j.ejps.2012.10.026

Paper

A novel approach to improve the pharmacokinetic properties of 8-chloro-adenosine by the dual combination of lipophilic derivatisation and liposome formulation.

Published Jan 23, 2013 · Yuan-yuan Jiao, Xue-qing Wang, Wan-Liang Lu

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Q1 SJR score

10

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Non-RCT

Animal Study

Study Snapshot

Lipophilic derivatization and incorporation of 8-chloro-adenosine into pegylated liposomes effectively improves the bioavailability of 8-chloro-adenosine for hematologic and solid tumor treatments.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

A novel approach to improve the pharmacokinetic properties of 8-chloro-adenosine by the dual combination of lipophilic derivatisation and liposome formulation.

Sign up to use Study Snapshot

References

A unique RNA-directed nucleoside analog is cytotoxic to breast cancer cells and depletes cyclin E levels

8-Cl-Ado, a unique RNA-directed nucleoside analog, shows potential as an effective agent for treating breast cancer by inhibiting RNA synthesis and depleting cyclin E levels.

The Ribonucleoside Analog, 8-Chloro-Adenosine, Inhibits the mTOR Pathway and Induces Autophagy.

8-Cl-Ado effectively inhibits breast cancer cell growth by inducing autophagy, promoting nutrient restoration and reducing energy depletion.

Preclinical activity of 8‐chloroadenosine with mantle cell lymphoma: roles of energy depletion and inhibition of DNA and RNA synthesis

8-chloroadenosine may promote cell death and inhibit growth of mantle cell lymphoma cell lines by reducing ATP levels and inhibiting DNA and RNA synthesis.

Inhibition of CHK1 kinase by Gö6976 converts 8-chloro-adenosine-induced G2/M arrest into S arrest in human myelocytic leukemia K562 cells.

Inhibiting CHK1 kinase by Gö6976 can promote DNA damage and convert G2/M checkpoint into intra-S-phase checkpoint in human myelocytic leukemia K562 cells, potentially aiding in combined therapy design.

Pten haploinsufficiency accelerates formation of high-grade astrocytomas.

Pten haploinsufficiency accelerates the formation of high-grade astrocytomas, potentially contributing to the etiology of primary glioblastoma.

Citations

Emerging insights on drug delivery by fatty acid mediated synthesis of lipophilic prodrugs as novel nanomedicines.

Lipophilic prodrugs, when designed with various unsaturated fatty acids and nanostructured delivery systems, can improve drug delivery, pharmacodynamics, and toxicity profile, leading to improved therapeutic efficacy.

Folic acid‐modified nonionic surfactant vesicles for gambogenic acid targeting: Preparation, characterization, and in vitro and in vivo evaluation

Folic acid-modified nonionic surfactant vesicles show potential as efficient carriers for targeted delivery of gambogenic acid to cancer cells, enhancing cytotoxicity and cellular uptake.

Preparation and evaluation of a Rubropunctatin-loaded liposome anticancer drug carrier

The developed Rubropunctatin-loaded liposome (R-Liposome) shows potential as a water-soluble, stable, and effective drug delivery vehicle for cancer treatment.

Lipid–drug conjugates and associated carrier strategies for enhanced antiretroviral drug delivery

Lipid-drug conjugates (LDCs) can enhance antiretroviral efficacy by improving oral bioavailability, lipophilicity, toxicity, and drug targeting when incorporated into suitable delivery systems.

Pharmacokinetics of lipid‐drug conjugates loaded into liposomes

Liposomal lipid-drug conjugates can improve a drug's pharmacokinetic profile and potentially enhance its therapeutic index and efficacy.